|
ICON has successfully conducted over 1,900 studies and over 2,300 consultancy engagements across all major therapeutic areas, including anti-infectives, CNS, cardiovascular, endocrinology, gastroenterology, immunology and transplant. |
|
|
|
ICON has performed 240 studies in metabolic disorders with over 107,000 patients across 13,648 sites in the last five years. |
|
|
|
ICON off ers a new electronic solution to expedite clinical trial adjudication enabling sponsors to comply with recent FDA Guidance on Diabetes Trials. |
|
|
|
ICON Central Laboratories has performed 100 diabetes studies with 34,400 patients across 3,040 sites in over 30 countries. |
|
|
|
ICON’s global investigator database includes over 85 organ transplant investigative sites across more than 20 countries. We have worked with a wealth of specialty investigators in the areas of renal transplantation, hematology (stem cell and bone marrow transplantation), abdominal transplantation, hepatologic transplantation, and neurological transplantation. |
|
|
|
ICON has extensive experience in conducting solid organ transplant studies in the following indications:
• Kidney transplantation |
• Heart transplantation |
• Kidney/pancreas transplantation |
• Bladder transplantation |
• Liver transplantation |
• Stem cell transplantation |
|
|
|
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis
of programs that support clinical development-from compound selection to Phase I-IV clinical studies.
ICON currently has over 6,500 employees, operating from 71 locations in 38 countries.
Further information is available at www.iconplc.com |
|
